Patents by Inventor Geoffrey M. Nichol

Geoffrey M. Nichol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Self-Assembling Nanoparticles Based On Amphiphilic Peptides
    Publication number: 20250127887
    Abstract: The present disclosure relates to a vaccine comprising an amphiphile having the formula S-[B]-[U]-H and at least one peptide antigen conjugate having the formula selected from [S]-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-[S], wherein the amphiphile and/or the at least one peptide antigen conjugate comprises a dendron amplifier. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, an infectious disease, a cardiovascular disease, or a neurodegenerative disease.
    Type: Application
    Filed: February 16, 2022
    Publication date: April 24, 2025
    Applicants: Barinthus Biotherapeutics North America, Inc., The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Geoffrey M. Lynn, Sarah R. Nichols, Vincent L. Coble, Andrew S. Ishizuka, Hugh Clarke Welles, Robert N. Goddu, Christopher Martin O’Brien Garliss, Ramiro Andrei Ramirez-Valdez
  • CTLA-4 antibody dosage escalation regimens
    Patent number: 9573999
    Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: February 21, 2017
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Geoffrey M. Nichol, Israel Lowy
  • CTLA-4 ANTIBODY DOSAGE ESCALATION REGIMENS
    Publication number: 20150246972
    Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Inventors: Geoffrey M. Nichol, Israel Lowy
  • CTLA-4 antibody dosage escalation regimens
    Patent number: 9062111
    Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 23, 2015
    Assignee: MEDAREX, L.L.C.
    Inventors: Geoffrey M. Nichol, Israel Lowy
  • CTLA-4 ANTIBODY DOSAGE ESCALATION REGIMENS
    Publication number: 20120100101
    Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.
    Type: Application
    Filed: December 22, 2011
    Publication date: April 26, 2012
    Inventors: Geoffrey M. Nichol, Israel Lowy
  • CTLA-4 antibody dosage escalation regimens
    Patent number: 8110194
    Abstract: A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: February 7, 2012
    Assignee: Medarex, Inc.
    Inventors: Geoffrey M. Nichol, Israel Lowy
  • Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of disease
    Patent number: 7744875
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: June 29, 2010
    Assignee: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol
  • Surrogate Therapeutic Endpoint For Anti-CTLA-4 Based Immunotherapy Of Disease
    Publication number: 20090074752
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Application
    Filed: October 27, 2008
    Publication date: March 19, 2009
    Applicant: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol
  • Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
    Patent number: 7465446
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: December 16, 2008
    Assignee: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol
  • Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
    Publication number: 20040241169
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Application
    Filed: May 27, 2004
    Publication date: December 2, 2004
    Applicant: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol